AgingResearch.NewsJoin free

Osk partial reprogramming

Intervention

1 paper6 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funders: National Heart, Lung, and Blood Institute and 4 more
  • Animals1

Outcomes

6

endothelial-to-mesenchymal transition

downin human cells1

1 study

  1. Osk partial reprogramming decreases endothelial-to-mesenchymal transition in human cells.

    “Single-cell RNA analysis showed that OSK alleviated EC senescence and EndMT, restoring their phenotypes in human aortic ECs from patients with hypertension.”

    Cellscells from patients with hypertensionaortic endothelial cell

    Single-Short Partial Reprogramming of the Endothelial Cells Decreases Blood Pressure via Attenuation of EndMT in Hypertensive Mice

    Circulation research3 Sep 2025

Cellular senescence

downin human cells1

1 study

  1. Osk partial reprogramming decreases cellular senescence in human cells.

    “Single-cell RNA analysis showed that OSK alleviated EC senescence and EndMT, restoring their phenotypes in human aortic ECs from patients with hypertension.”

    Cellscells from patients with hypertensionaortic endothelial cell

    Single-Short Partial Reprogramming of the Endothelial Cells Decreases Blood Pressure via Attenuation of EndMT in Hypertensive Mice

    Circulation research3 Sep 2025

More on Cellular senescence

Nitric oxide

upin human cells1

1 study

  1. Osk partial reprogramming increases nitric oxide in human cells.

    “OSK-treated hypertensive human aortic ECs showed high eNOS activation and NO production, with low reactive oxygen species (ROS) formation.”

    Cellscells from patients with hypertensionaortic endothelial cell

    Single-Short Partial Reprogramming of the Endothelial Cells Decreases Blood Pressure via Attenuation of EndMT in Hypertensive Mice

    Circulation research3 Sep 2025

More on Nitric oxide

Endothelial cell migration

downin cells1

1 study

  1. Osk partial reprogramming decreases endothelial cell migration in cells.

    “OSK overexpression induced partial EC reprogramming in vitro, and these cells had lower migratory capability.”

    Cellslentiviral vectorsendothelial cell

    Single-Short Partial Reprogramming of the Endothelial Cells Decreases Blood Pressure via Attenuation of EndMT in Hypertensive Mice

    Circulation research3 Sep 2025

Resistance artery hypercontractility

downin mice1

1 study

  1. Osk partial reprogramming decreases resistance artery hypercontractility in mice.

    “OSK treatment of BPH/2J mice reduced blood pressure and resistance arteries hypercontractility, via the attenuation of endothelial-to-mesenchymal transition and elastin breaks.”

    AnimalsBPH/2J hypertensive micelentiviral vectorsresistance artery10 days post-infectionmale and females

    Single-Short Partial Reprogramming of the Endothelial Cells Decreases Blood Pressure via Attenuation of EndMT in Hypertensive Mice

    Circulation research3 Sep 2025

Blood pressure

downin mice1

1 study

  1. Osk partial reprogramming decreases blood pressure in mice.

    “OSK treatment of BPH/2J mice reduced blood pressure and resistance arteries hypercontractility, via the attenuation of endothelial-to-mesenchymal transition and elastin breaks.”

    AnimalsBPH/2J hypertensive micelentiviral vectors10 days post-infectionmale and females

    Single-Short Partial Reprogramming of the Endothelial Cells Decreases Blood Pressure via Attenuation of EndMT in Hypertensive Mice

    Circulation research3 Sep 2025

Latest

Related